Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand

被引:14
作者
Churdboonchart, V
Moss, RB
Sirawaraporn, W
Smutharaks, B
Sutthent, R
Jensen, FC
Vacharak, P
Grimes, J
Theofan, G
Carlo, DJ
机构
[1] Mahidol Univ, Fac Sci, Dept Pathobiol, Bangkok 10400, Thailand
[2] Immunol Response Corp, Carlsbad, CA USA
[3] Mahidol Univ, Remune Trial Ctr, Bangkok 10400, Thailand
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
Asia; CD4; CD8; therapy; vaccine;
D O I
10.1097/00002030-199812000-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To examine the effect of treatment with an inactivated, gp120-depleted, HIV-1 immunogen (Remune) in 30 Thai subjects infected with HIV-1 subtype E. Design: Sixty-week open-label study. Methods: Thirty HIV-positive volunteers with CD4 cell counts greater than or equal to 300 x 10(6)/l were given intramuscular injections of Remune into the triceps muscle on day 1 and then at weeks 4, 8, 12, 24, 36, 48 and 60. Results: Treatment with Remune was well-tolerated and augmented HIV-l-specific immune responses. Furthermore, subjects had a significant increase in CD4 cell count (P < 0.0001), CD4 cell percentage (P < 0.0001), CD8 cell percentage (P < 0.0001), and body weight (P < 0.0001) compared with pretreatment levels. Fourteen subjects with detectable viral load at day 1 showed a decrease at week 60 (P = 0.04). Retrospective Western blot analysis showed 23 subjects with increased intensity of antibody bands and 15 patients showed development of new reactivities to HIV proteins, especially towards p17 and p15. Conclusion: These results indicate that HIV-specific immune-based therapeutic approaches such as Remune should be further examined in countries with different clades of HIV-1 and where access to antiviral drug therapies is limited. (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:1521 / 1527
页数:7
相关论文
共 30 条
[1]  
[Anonymous], 1997, AIDS, V11, pS13
[2]   Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 [J].
Binley, JM ;
Klasse, PJ ;
Cao, YZ ;
Jones, I ;
Markowitz, M ;
Ho, DD ;
Moore, JP .
JOURNAL OF VIROLOGY, 1997, 71 (04) :2799-2809
[3]   HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant [J].
Choi, DJ ;
Dube, S ;
Spicer, TP ;
Slade, HB ;
Jensen, FC ;
Poiesz, BJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (04) :357-361
[4]   ANTIBODIES AGAINST DENGUE VIRAL-PROTEINS IN PRIMARY AND SECONDARY DENGUE HEMORRHAGIC-FEVER [J].
CHURDBOONCHART, V ;
BHAMARAPRAVATI, N ;
PEAMPRAMPRECHA, S ;
SIRINAVIN, S .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 44 (05) :481-493
[5]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[6]   GENETIC-RELATIONSHIPS DETERMINED BY A DNA HETERODUPLEX MOBILITY ASSAY - ANALYSIS OF HIV-1 ENV GENES [J].
DELWART, EL ;
SHPAER, EG ;
LOUWAGIE, J ;
MCCUTCHAN, FE ;
GREZ, M ;
RUBSAMENWAIGMANN, H ;
MULLINS, JI .
SCIENCE, 1993, 262 (5137) :1257-1261
[7]  
FERBAS J, 1997, C ADV AIDS VACC DEV
[8]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[9]  
KALAMS SA, 1998, KEYSTONE S HIV PATHO
[10]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+